cilomilast has been researched along with Disease Models, Animal in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (66.67) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Alonso, JM; Andrés, JI; Boeckx, G; Cools, M; de Chaffoy, D; De Clerck, F; Deroose, F; Díaz, A; Diels, G; Fernández, J; Freyne, EJ; Iturrino, L; Martínez, P; Matesanz, E; Megens, A; Peeters, D; Petit, D; Somers, M; Stoppie, P; Van Wauwe, J | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Alalaiwe, A; Elzoghby, AO; Fang, JY; Hsu, CY; Hwang, TL; Lin, CY | 1 |
| Harada, D; Ikeda, Y; Kobayashi, K; Manabe, H; Nosaka, Y | 1 |
| Balachandran, S; Chaudhary, S; Dastidar, SG; Gupta, N; Nanda, K; Palle, V; Rajagopal, D; Ray, A; Seth, MK; Sharma, P; Shirumalla, R | 1 |
| Bertin, B; Bertrand, CP; Bouget, A; Burnouf, C; Doherty, AM; Dubuit, JP; Julien-Larose, C; Lagente, V; Leportier, C; Martin, B; Moreau, F; Ouaged, M; Pruniaux, MP; Rocher, MN | 1 |
| Al-tamari, HM; Dumitrascu, R; Ghofrani, HA; Grimminger, F; Guenther, A; Pullamsetti, SS; Schermuly, RT; Seeger, W; Udalov, S; Voswinckel, R; Weissmann, N | 1 |
| Hirano, Y; Kobayashi, M; Kobayashi, S; Kubo, S; Shimizu, Y; Takahashi, K | 1 |
| Amparo, F; Chauhan, SK; Chen, Y; Dana, R; Dohlman, TH; Hua, J; Okanobo, A; Sadrai, Z; Stevenson, W | 1 |
| Bäumer, W; Ehinger, AM; Gorr, G; Hoppmann, J; Kietzmann, M; Rundfeldt, C | 1 |
| Devillier, P | 1 |
| Bäumer, W; Braun, M; Kietzmann, M; Seegers, U; Tschernig, T | 1 |
| Beume, R; Bundschuh, DS; Marx, D; Wohlsen, A; Wollin, L | 1 |
| Artola, M; Berthelier, C; Bertrand, CP; Eichholtz, T; Lagente, V; Leclerc, O; Planquois, JM; Schmidlin, F | 1 |
| Guan, Q; Montrose, DC; Quilley, J; Rajagopalan, S; Smith, CJ; Zhao, H | 1 |
| Abraham, WM; Claveau, D; Dias, R; Dubé, D; Gallant, M; Girard, Y; Goetghebeur, P; Huang, Z; Jones, T; Lacombe, P; Laliberte, F; Liu, S; Macdonald, D; Mancini, JA; Ng, K; Nicholson, DW; Otu, F; Styhler, A; Turner, MJ; Young, RN; Zhang, L | 1 |
| Chapman, R; Fine, J; Jones, H; Kreutner, W; Kung, TT; Minnicozzi, M; Spond, J | 1 |
| Cassali, GD; Poole, S; Souza, DG; Teixeira, MM | 1 |
1 review(s) available for cilomilast and Disease Models, Animal
| Article | Year |
|---|---|
[Physiopathology of COPD: choosing the right therapeutic targets].
Topics: Adrenal Cortex Hormones; Aged; Albuterol; Animals; Bacterial Infections; Bronchodilator Agents; Carboxylic Acids; Cyclohexanecarboxylic Acids; Disease Models, Animal; Drug Therapy, Combination; Humans; Inflammation; Mucociliary Clearance; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Alveoli; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Randomized Controlled Trials as Topic; Rats; Rolipram; Salmeterol Xinafoate; Smoking; Theophylline; Time Factors | 2003 |
17 other study(ies) available for cilomilast and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Topical; Animals; Anti-Inflammatory Agents; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Dose-Response Relationship, Drug; Ear Diseases; Enzyme Inhibitors; Humans; Imidazoles; Inflammation; Inhibitory Concentration 50; Rats; Structure-Activity Relationship | 2002 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Oleic acid as the active agent and lipid matrix in cilomilast-loaded nanocarriers to assist PDE4 inhibition of activated neutrophils for mitigating psoriasis-like lesions.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Disease Models, Animal; Drug Carriers; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neutrophil Activation; Neutrophils; Nitriles; Oleic Acid; Phosphodiesterase 4 Inhibitors; Psoriasis | 2019 |
Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.
Topics: Aminopyridines; Animals; Benzamides; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; Dermatitis; Dermatitis, Contact; Disease Models, Animal; Eosinophil Peroxidase; Interleukin-4; Male; Mice; Mice, Inbred BALB C; Nitriles; Peroxidase; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Picryl Chloride; Rolipram | 2008 |
Pharmacology of a novel, orally active PDE4 inhibitor.
Topics: Animals; Carboxylic Acids; Cell Line, Transformed; Cyclic AMP; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dogs; Female; Guinea Pigs; Humans; Inflammation; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Nitriles; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Rolipram; Tumor Necrosis Factor-alpha; Vomiting | 2009 |
Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.
Topics: Administration, Oral; Animals; Azepines; Carboxylic Acids; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Inflammation; Inhibitory Concentration 50; Lipopolysaccharides; Male; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Eosinophilia; Rats; Rats, Inbred BN; Rolipram; Tumor Necrosis Factor-alpha | 2010 |
Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.
Topics: Animals; Bleomycin; Carboxylic Acids; Collagen Type I; Collagen Type I, alpha 1 Chain; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Disease Models, Animal; Interleukin-1beta; Interleukin-6; Lung; Male; Mice; Mice, Inbred C57BL; Nitriles; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pneumonia; Pulmonary Fibrosis; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2010 |
Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor.
Topics: Aminopyridines; Animals; Anti-Asthmatic Agents; Benzamides; Bronchial Hyperreactivity; Bronchoconstriction; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Eosinophils; Female; Guinea Pigs; In Vitro Techniques; Lung; Male; Naphthyridines; Nitriles; Ovalbumin; Phosphodiesterase 4 Inhibitors; Rats; Trachea | 2012 |
PDE4 inhibition suppresses IL-17-associated immunity in dry eye disease.
Topics: Animals; Conjunctiva; Cornea; Cyclohexanecarboxylic Acids; Disease Models, Animal; Disease Progression; Dry Eye Syndromes; Female; Flow Cytometry; Gene Expression Regulation; Immunity, Innate; Immunohistochemistry; Interleukin-7; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Nitriles; Ophthalmic Solutions; Phosphodiesterase 4 Inhibitors; Real-Time Polymerase Chain Reaction; RNA | 2012 |
AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Administration, Topical; Amides; Animals; Bronchodilator Agents; Carboxylic Acids; Cattle; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cytokines; Dermatitis, Allergic Contact; Disease Models, Animal; Ear; Female; Indoles; Inflammation; Inflammation Mediators; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Nitriles; Time Factors; Toluene | 2003 |
TARC and RANTES, but not CTACK, are induced in two models of allergic contact dermatitis. Effects of cilomilast and diflorasone diacetate on T-cell-attracting chemokines.
Topics: Animals; Betamethasone; Bronchodilator Agents; Carboxylic Acids; Chemokine CCL17; Chemokine CCL27; Chemokine CCL5; Chemokines; Chemokines, CC; Cyclohexanecarboxylic Acids; Dermatitis, Allergic Contact; Disease Models, Animal; Female; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Nitriles; T-Lymphocyte Subsets | 2004 |
Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Aminopyridines; Animals; Benzamides; Bronchial Spasm; Bronchoalveolar Lavage Fluid; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Immunization; Male; Neutrophils; Nitriles; Ovalbumin; Phosphodiesterase Inhibitors; Pneumonia; Pyridines; Rats; Respiratory Hypersensitivity; Rolipram; Serotonin; Treatment Outcome; Tumor Necrosis Factor-alpha | 2006 |
Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Bronchoalveolar Lavage Fluid; Carboxylic Acids; Chromosome Deletion; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Dexamethasone; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Matrix Metalloproteinase 12; Metalloendopeptidases; Mice; Mice, Inbred C57BL; Neutrophils; Nitriles; Pneumonia; Pulmonary Disease, Chronic Obstructive; Smoking | 2006 |
Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Angioplasty, Balloon; Animals; Aorta; Carboxylic Acids; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; In Vitro Techniques; Male; Milrinone; Nitriles; Phosphodiesterase Inhibitors; Phosphorylation; Quinolones; Rats; Rats, Sprague-Dawley; Tetrazoles; Up-Regulation; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2007 |
L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Apoenzymes; Ascaris suum; Asthma; Benzamides; Bronchoconstriction; Carboxylic Acids; Cognition Disorders; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Guinea Pigs; Humans; Inhibitory Concentration 50; Injections, Intraperitoneal; Interferon-gamma; Male; Molecular Structure; Nitriles; Ovalbumin; Polymerase Chain Reaction; Quinolines; Rats; Sensitivity and Specificity; Sheep | 2007 |
Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.
Topics: Adrenalectomy; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Humans; Inflammation; Interleukin-1; Lung Diseases; Lung Diseases, Obstructive; Male; Neutrophils; Nitriles; Phosphodiesterase Inhibitors; Rats; Rats, Sprague-Dawley; Respiratory Distress Syndrome; Rolipram; Tumor Necrosis Factor-alpha | 2001 |
Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Capillary Permeability; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Immune Sera; Male; Neutrophils; Nitriles; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Reperfusion Injury; Rolipram; Survival Rate; Tumor Necrosis Factor-alpha | 2001 |